- Home
- INDP vs APVO Comparison
INDP vs APVO Comparison
Compare INDP & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- APVO
- Stock Information
- Founded
- INDP 2000
- APVO 2016
- Country
- INDP United States
- APVO United States
- Employees
- INDP N/A
- APVO N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- INDP Health Care
- APVO Health Care
- Exchange
- INDP Nasdaq
- APVO Nasdaq
- Market Cap
- INDP 6.0M
- APVO 4.9M
- IPO Year
- INDP N/A
- APVO N/A
- Fundamental
- Price
- INDP $3.62
- APVO $1.78
- Analyst Decision
- INDP Strong Buy
- APVO
- Analyst Count
- INDP 2
- APVO 0
- Target Price
- INDP $238.00
- APVO N/A
- AVG Volume (30 Days)
- INDP 1.4M
- APVO 16.3M
- Earning Date
- INDP 11-11-2025
- APVO 11-06-2025
- Dividend Yield
- INDP N/A
- APVO N/A
- EPS Growth
- INDP N/A
- APVO N/A
- EPS
- INDP N/A
- APVO N/A
- Revenue
- INDP N/A
- APVO N/A
- Revenue This Year
- INDP N/A
- APVO N/A
- Revenue Next Year
- INDP N/A
- APVO N/A
- P/E Ratio
- INDP N/A
- APVO N/A
- Revenue Growth
- INDP N/A
- APVO N/A
- 52 Week Low
- INDP $2.22
- APVO $1.32
- 52 Week High
- INDP $58.24
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- INDP 45.47
- APVO 53.33
- Support Level
- INDP $2.86
- APVO $1.41
- Resistance Level
- INDP $4.50
- APVO $1.49
- Average True Range (ATR)
- INDP 0.99
- APVO 0.18
- MACD
- INDP 0.25
- APVO 0.04
- Stochastic Oscillator
- INDP 19.01
- APVO 35.04
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.